The North America Thyroid Ablation Devices Market would witness market growth of 12.5% CAGR during the forecast period (2022-2028).
Certain factors aid in the higher prevalence of thyroid cancer. When an individual is exposed to radiation or receives radiation to the neck and head as a baby or young child, the chances of getting thyroid cancer increase. Moreover, if a person has thyroid cancer or thyroid illness in their family, has a goiter history, or possesses a genetic disorder like the RET gene-related multiple endocrine neoplasia type 2 syndrome (MEN2), their chances of acquiring thyroid cancer increase.
Due to the rising incidence of thyroid nodules and thyroid cancer, there is a rising demand for both thyroid ablation treatments and devices. Additionally, the introduction of technologically advanced ablation methods and the growing inclination for less invasive surgeries are anticipated to fuel market expansion. Presently, the most popular and effective methods for treating thyroid cancer and nodules are ablation methods.
The CDC claims that the leading cause of death and disability/impairment in the US is a chronic disease. Therefore, RFA technology operations will probably be needed as a result of the rise in chronic diseases in the US. In the United States, there were reportedly 915,664 thyroid cancer patients in 2019. In this nation, thyroid cancer affects about 33,000 women and 12,000 men annually, killing about 950 men and 1,100 women. Thyroid cancer was previously increasing more quickly than any other malignancy in the US. Increased detection through imaging tests like MRI or CT scans performed for other medical issues was mostly responsible for this. The strict diagnostic criteria have helped in decreasing the incidence of thyroid cancer by roughly 2% per year since 2014. This has helped in more people adopting for thyroid cancer and nodules ablation treatment.
The US market dominated the North America Thyroid Ablation Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $78,493.1 Thousands by 2028. The Canada market is poised to grow at a CAGR of 15% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 14% during (2022 - 2028).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Specialty Centers and Others. Based on Type, the market is segmented into Radiofrequency Ablation, Microwave Ablation and Others. Based on Application, the market is segmented into Thyroid Cancer and Thyroid Nodules. Based on Product, the market is segmented into Thermal-based Devices and Non-thermal-based Devices. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Thyroid Ablation Devices Market is Estimated to reach $289.9 Million by 2028, at a CAGR of 13%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Boston Scientific Corporation, Integra LifeSciences Holdings Corporation, Johnson & Johnson, Theraclion SA, Olympus Corporation, Terumo Corporation, BVM Medical Limited, MedWaves, Inc., and STARmed Co. Ltd.
By End-use
By Type
By Application
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
